Fig. 4.

Biological activities of HA22-LR-8M. (A) Cytotoxic activity of HA22 (●) and HA22-LR-8M (□) on CA46 cells. (B) Cytotoxic activity (IC₅₀) of HA22 and HA22-LR-8M on CLL cells from 25 patients. The bar indicates the median IC₅₀ value. (C) Antitumor activity of HA22 and HA22-LR-8M at low doses. Groups of 8 SCID mice bearing CA46 tumors were treated QODx3 (arrows), with 0.2% mouse serum albumen (MSA) in PBS (■), HA22 at 0.3 mg/kg (▲), or HA22-LR-8M at 0.3 mg/kg (●), 0.6 mg/kg (△) or 1.0 mg/kg (○). (D) Antitumor activity of HA22 and HA22-LR-8M at high doses. Groups of eight mice with CA46 tumors were treated QODx3 (arrows), with 0.2% MSA in PBS (■), HA22 at 0.4 mg/kg (▲), or HA22-LR-8M at 2.5 mg/kg (●) or 5.0 mg/kg (○). Data are expressed as the mean ± SD.